Two-stage Vectors Deliver Gene Silencing Therapy to Tumors

Haifa Shen and Mauro Ferrari led a team of investigators that created a two-stage delivery vehicle capable of ferrying an agent that targets this protein to triple negative breast tumors. When administered to mice bearing human breast tumors, the drug-bearing…

Haifa Shen and Mauro Ferrari led a team of investigators that created a two-stage delivery vehicle capable of ferrying an agent that targets this protein to triple negative breast tumors. When administered to mice bearing human breast tumors, the drug-bearing vector stopped the production of the ATM protein and greatly inhibited the growth of what otherwise is an aggressive cancer. The researchers published the results of their work in the journal Small. Dr. Ferrari is co-principal investigator of the Texas Center for Cancer Nanomedicine, one of nine Centers of Cancer Nanotechnology Excellence funded by the National Cancer Institute.

To stop the production of ATM, the researchers created a short interfering RNA (siRNA) that targets the messenger RNA that codes for this protein. siRNA-based therapies have shown promise for treating cancer, but delivering them to tumors at therapeutic levels has proven challenging. Dr. Shen and Dr. Ferrari solved this problem using a two-stage delivery vehicle consisting of a nanoscale liposome and a disc-shaped, nanoporous silicon microparticle. The researchers use the liposome to encapsulate the siRNA agent and they take advantage of the biocompatible silicon microparticles to safely ferry the liposomes through the blood stream and deposit them just outside of the tumors.Because of their disc shape, the silicon microparticles accumulate efficiently in the blood vessels that surround tumors. In earlier work, Dr. Ferrari and his Texas Center for Cancer Nanomedicine colleague Paulo Decuzzi had shown that approximately between six and 10 percent of an injected dose of silicon microparticles accumulate in the tumor vasculature compared to less than 0.1 percent of conventionally administered drug. Once the microparticles settle around the tumor, they gradually degrade into non-toxic materials and slowly release the liposomes. The liposomes then migrate into the tumors, where they are taken up by cancer cells and release their siRNA payload.While experiments in tumor bearing mice showed that this two-stage delivery system was effective at suppressing tumor growth, they also demonstrated that it did not trigger a potentially dangerous immune response that is often seen with siRNA therapies. Additionally, during the four-week experiments, body weight, blood chemistry, and tissue histology did not reveal significant toxicities which are often associated with chemotherapies.####About The National Cancer Institute (NCI)To help meet the goal of reducing the burden of cancer, the National Cancer Institute (NCI), part of the National Institutes of Health, is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer.The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.
For more information, please click
Contacts:National Cancer InstituteOffice of Technology & Industrial RelationsATTN: NCI Alliance for Nanotechnology in CancerBuilding 31, Room 10A4931 Center Drive , MSC 2580Bethesda , MD 20892-2580
Copyright © The National Cancer Institute (NCI)
If you have a comment, please us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Bookmark:

Related Links

Related News PressNews and information
March 9th, 2013
March 9th, 2013
March 9th, 2013
March 9th, 2013
Govt.-Legislation/Regulation/Funding/Policy
March 9th, 2013
March 9th, 2013
March 9th, 2013
March 9th, 2013
Nanomedicine
March 9th, 2013
March 9th, 2013
March 8th, 2013
March 7th, 2013
Discoveries
March 9th, 2013
March 9th, 2013
March 9th, 2013
March 9th, 2013
Announcements
March 9th, 2013
March 9th, 2013
March 9th, 2013
March 9th, 2013